Altasciences Initiates Phase I Study in Healthy Normal Subjects for ST-2427, a Non-Opioid Analgesic for Acute Pain
13.5.2021 19:31:00 EEST | Business Wire | Press release
Altasciences is pleased to support SiteOne Therapeutics with a Phase I, randomized, double-blind, placebo-controlled study in healthy adults to evaluate the safety, tolerability, and pharmacokinetics of ST-2427. ST-2427 is a highly selective inhibitor of NaV1.7 for the management of moderate-to-severe pain; by selectively targeting NaV1.7, ST-2427 aims to stop the electrical signals responsible for pain before they reach the central nervous system.
Amy Denvir, General Manager of Altasciences’ Kansas City clinical site, says, “We are proud to partner with SiteOne Therapeutics and help move this important therapeutic into clinical trials. Helping bring to market a new approach that may provide a non-opioid option to treat moderate- to-severe pain is an exciting prospect, and we look forward to delivering this ground-breaking research.”
Click here to read the SiteOne press release.
Altasciences has designed and conducted hundreds of first-in-human trials by offering comprehensive, full service, early development solutions. With a focus on developing sound strategies combined with operational efficiencies, the company minimizes the time taken to make critical go/no-go decisions by harmonizing clinical pharmacology services, biomarker capabilities, PK/PD analysis expertise, and program knowledge.
About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005827/en/
Contact information
Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alpaca Launches German Equities Trading via Deutsche Börse Xetra21.7.2026 14:00:00 EEST | Press release
Alpaca, a global leader in agent-first brokerage infrastructure, today announced that its broker partners can now offer trading in German equities through Deutsche Börse Xetra, providing access to one of Europe’s largest equity markets. The launch marks the first phase of Alpaca’s broader global equities initiative. In the coming months, Alpaca expects to roll out access to additional major international exchanges, including Hong Kong Stock Exchange, London Stock Exchange, Saudi Exchange, Euronext Paris, and Korea Exchange, with additional markets planned. Germany is the largest economy in Europe and the third largest in the world, behind the United States and China. Through Xetra, Alpaca’s broker partners can offer access to hundreds of German equities, including shares in companies such as SAP, Siemens, Allianz, BMW, Deutsche Bank, Adidas, and Bayer, across sectors including technology, manufacturing, financial services, and healthcare. "Investors increasingly expect access beyond U.
SIAL Paris 2026: the Event That Sheds Light on and Accelerates the Global Agri-food Industry21.7.2026 13:10:00 EEST | Press release
With just a few months to go until SIAL Paris 2026 (17–21 October, Paris Nord Villepinte), the trade fair has unveiled the findings of its new SIAL Insights 2026 report, an international analysis identifying ten major trends set to bring about lasting change to food markets and consumer behavior. Compiled using exclusive data from Kantar Food 360™, Circana and ProtéinesXTC, the report highlights a more personalised, functional and experiential approach to food, whilst revealing the new trade-offs consumers are making in the face of economic, health and environmental challenges. The 10 key insights into food in 2026 1. Healthy eating: fuel for a high-performing body Consumers are seeking measurable benefits: protein, fiber, energy, immunity or digestive health. 2. The ‘gut brain’: food for mental wellbeing Sleep, stress management, hormonal balance and cognitive performance now influence dietary choices. 3. Pleasure as a conscious experience Premium taste experiences, bold flavors and c
Sagepath Reply Recognized in the 2026 Gartner® Market Guide for Strategic Website Agencies21.7.2026 11:00:00 EEST | Press release
Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. This marks the third time Sagepath Reply has been named in the Market Guide, following its previous inclusions in 2023 and 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721481392/en/ Sagepath Reply, a digital experience agency part of the Reply Group, has been included in the 2026 Gartner Market Guide for Strategic Website Agencies. Gartner, a company delivering actionable, objective insight to executives and their teams, defines strategic website agencies as “service providers dedicated to developing website strategies that deliver relevant digital experiences to external audiences. These agencies bundle their strategic marketing services with an array of complementary offerings to support their clients’ needs around website design, development, search value and co
ClickHouse Announced as Principal Partner & Front of Shirt Sponsor of Fulham Football Club21.7.2026 11:00:00 EEST | Press release
Fulham Football Club is proud to announce ClickHouse, a global technology company specialising in real-time analytics, data infrastructure and AI applications, as its newest Principal Partner and Front of Shirt Sponsor of the Men’s First Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260721902779/en/ ClickHouse announced as Principal Partner and Front of Shirt Sponsor of Fulham Football Club This multi-year partnership will see ClickHouse take pride of place on the front of the Men’s First Team home, away and third kits. ClickHouse will also feature across Craven Cottage, the Club’s digital channels, matchday assets and a range of supporter-facing experiences throughout the partnership. The Fulham FC home kit will be released on Thursday 23rd July 2026, keep an eye on the Club’s Instagram for updates. Our collaboration reflects Fulham’s continued focus on innovation, performance and delivering engaging experiences for
European Commission Approves Crysvita ® (burosumab) for Infants with X-linked Hypophosphataemia in the European Union21.7.2026 10:00:00 EEST | Press release
Kyowa Kirin EMEA, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151), today announced that the European Commission (EC) has approved an expansion of the indication for Crysvita® (burosumab) for the treatment of X-linked hypophosphataemia (XLH), to include infants from 1 month to 1 year of age across the European Union and European Economic Area. The approval represents an important step forward for infants living with XLH, a rare, progressive genetic disease that can affect skeletal development from an early age. Earlier diagnosis and treatment are considered important in XLH given the potential impact of the disease on skeletal development during infancy and childhood. XLH is a rare, progressive, lifelong genetic disease characterised by phosphate wasting that can impair bone mineralisation from an early age, leading to skeletal deformities, impaired growth and other serious complications. Clinical manifestations of XLH can emerge during infancy and early childhood, with pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom